Foxx Development Holdings Inc. (NASDAQ:FOXX) Short Interest Update

Foxx Development Holdings Inc. (NASDAQ:FOXXGet Free Report) was the target of a large drop in short interest in the month of July. As of July 31st, there was short interest totaling 19,770 shares, a drop of 41.2% from the July 15th total of 33,622 shares. Based on an average daily volume of 8,351 shares, the days-to-cover ratio is presently 2.4 days. Currently, 0.4% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Foxx Development from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Foxx Development has a consensus rating of “Sell”.

Get Our Latest Stock Report on FOXX

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Foxx Development stock. JPMorgan Chase & Co. raised its stake in shares of Foxx Development Holdings Inc. (NASDAQ:FOXXFree Report) by 170.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,947 shares of the company’s stock after purchasing an additional 3,121 shares during the quarter. JPMorgan Chase & Co. owned 0.07% of Foxx Development worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 60.44% of the company’s stock.

Foxx Development Stock Performance

Foxx Development stock opened at $2.57 on Monday. Foxx Development has a fifty-two week low of $1.71 and a fifty-two week high of $7.90. The stock has a market cap of $18.09 million, a P/E ratio of -0.37 and a beta of -0.35. The firm’s fifty day moving average price is $3.00 and its 200-day moving average price is $4.07.

Foxx Development (NASDAQ:FOXXGet Free Report) last posted its quarterly earnings data on Wednesday, May 20th. The company reported ($5.19) earnings per share (EPS) for the quarter. The company had revenue of $8.67 million during the quarter.

About Foxx Development

(Get Free Report)

Foxx Development, Inc (NASDAQ: FOXX) operates as a contract manufacturer specializing in the design, assembly and distribution of medical devices and components. The company’s core business centers on phlebotomy and blood collection products, serving clinical laboratories, hospitals and diagnostic testing facilities. Its product portfolio includes evacuated blood collection tubes, safety-engineered winged blood collection sets, syringes and ancillary devices used in specimen collection and handling.

Founded in North Carolina, Foxx Development maintains a manufacturing and distribution campus in Apex, where it integrates engineering, quality control and regulatory compliance under one roof.

Featured Stories

Receive News & Ratings for Foxx Development Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foxx Development and related companies with MarketBeat.com's FREE daily email newsletter.